- Home
- CGAU vs ARQT Comparison
CGAU vs ARQT Comparison
Compare CGAU & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- ARQT
- Stock Information
- Founded
- CGAU 2002
- ARQT 2016
- Country
- CGAU Canada
- ARQT United States
- Employees
- CGAU N/A
- ARQT N/A
- Industry
- CGAU Precious Metals
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- ARQT Health Care
- Exchange
- CGAU Nasdaq
- ARQT Nasdaq
- Market Cap
- CGAU 1.6B
- ARQT 1.7B
- IPO Year
- CGAU N/A
- ARQT 2020
- Fundamental
- Price
- CGAU $7.11
- ARQT $13.82
- Analyst Decision
- CGAU Buy
- ARQT Strong Buy
- Analyst Count
- CGAU 2
- ARQT 6
- Target Price
- CGAU $12.00
- ARQT $18.80
- AVG Volume (30 Days)
- CGAU 959.3K
- ARQT 1.9M
- Earning Date
- CGAU 07-31-2025
- ARQT 08-13-2025
- Dividend Yield
- CGAU 2.80%
- ARQT N/A
- EPS Growth
- CGAU N/A
- ARQT N/A
- EPS
- CGAU 0.18
- ARQT N/A
- Revenue
- CGAU $1,208,123,000.00
- ARQT $212,819,000.00
- Revenue This Year
- CGAU N/A
- ARQT $61.15
- Revenue Next Year
- CGAU $8.11
- ARQT $37.98
- P/E Ratio
- CGAU $38.73
- ARQT N/A
- Revenue Growth
- CGAU 2.88
- ARQT 100.03
- 52 Week Low
- CGAU $5.41
- ARQT $7.86
- 52 Week High
- CGAU $7.82
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- CGAU 51.44
- ARQT 50.73
- Support Level
- CGAU $7.01
- ARQT $12.97
- Resistance Level
- CGAU $7.25
- ARQT $13.84
- Average True Range (ATR)
- CGAU 0.22
- ARQT 0.61
- MACD
- CGAU -0.04
- ARQT 0.02
- Stochastic Oscillator
- CGAU 16.90
- ARQT 51.64
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.